株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肝細胞増殖因子 (ヘパトポエチンA、肺線維芽細胞由来マイトジェン) :パイプライン製品の分析

Hepatocyte Growth Factor - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 363117
出版日 ページ情報 英文 76 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.10円で換算しております。
肝細胞増殖因子 (ヘパトポエチンA、肺線維芽細胞由来マイトジェン) :パイプライン製品の分析 Hepatocyte Growth Factor - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 76 Pages
概要

当レポートでは、肝細胞増殖因子 (ヘパトポエチンA、肺線維芽細胞由来マイトジェン) の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなど、体系的な情報を提供しています。

目次

イントロダクション

概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療分野別
  • 開発中の製品:適応別

パイプライン製品の概要

  • 後期段階の製品
  • 初期段階の製品

開発中の製品:企業別

開発中の製品:大学/研究機関別

治療薬の評価

  • 単剤/併用療法別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

  • Amgen Inc.
  • AnGes MG, Inc.
  • Kringle Pharma, Inc.
  • M3 Biotechnology, Inc.
  • Minerva Biotechnologies Corporation
  • Molecular Partners AG
  • ViroMed Co., Ltd.
  • Yooyoung Pharmaceutical Co., Ltd.

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

最新ニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AnGes Inc, H2 2019
  • Pipeline by Athira Pharma Inc, H2 2019
  • Pipeline by Helixmith Co Ltd, H2 2019
  • Pipeline by i2 Pharmaceuticals Inc, H2 2019
  • Pipeline by Kringle Pharma Inc, H2 2019
  • Pipeline by Minerva Biotechnologies Corp, H2 2019
  • Pipeline by Molecular Partners AG, H2 2019
  • Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Yooyoung Pharm Co Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC2041TDB

Summary

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. The latest report Hepatocyte Growth Factor - Pipeline Review, H2 2019, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 1, 3 and 2 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders and Metabolic Disorders which include indications Amyotrophic Lateral Sclerosis, Colorectal Cancer, Critical Limb Ischemia, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Advanced Malignancy, Alzheimer's Disease, Arteriosclerosis, Breast Cancer, Cervical Cancer, Colon Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Ischemic Foot Ulcers, Diabetic Neuropathic Pain, Gallbladder Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lymphedema, Lymphoma, Metastatic Cancer, Myocardial Infarction, Nasopharyngeal Cancer, Neuro Muscular Disorders, Non-Small Cell Lung Cancer, Parkinson's Disease, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Post-Operative Pain, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar and Thromboangiitis obliterans (Buerger disease).

Furthermore, this report also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
  • AnGes Inc
  • Athira Pharma Inc
  • Helixmith Co Ltd
  • i2 Pharmaceuticals Inc
  • Kringle Pharma Inc
  • Minerva Biotechnologies Corp
  • Molecular Partners AG
  • Yichang Humanwell Pharmaceutical Co Ltd
  • Yooyoung Pharm Co Ltd
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
  • beperminogene perplasmid - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • donaperminogene seltoplasmid - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy 1 to Activate HGF for Myocardial Infarction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KP-100IT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MP-0250 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NDX-1017 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NK-4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-186 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-188 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YYB-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 12, 2019: Molecular Partners provides update on its Multiple Myeloma drug candidate MP-0250 at R&D Day
  • Dec 09, 2019: Athira Pharma presents positive data for NDX-1017 in Alzheimer's patients at 2019 clinical trials on Alzheimer's disease (CTAD) conference
  • Dec 07, 2019: Molecular Partners presents updated results of MP0250 in patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting
  • Nov 20, 2019: Athira Pharma to present phase 1 data for NDX-1017 in oral presentation at 2019 clinical trials on Alzheimer's Disease (CTAD) Conference
  • Oct 07, 2019: Helixmith shows long-term safety and efficacy of VM202 for painful DPN patients in DPN phase 3-1b extension study
  • Oct 02, 2019: Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimers Patients
  • Sep 23, 2019: Helixmith: Topline results of DPN Phase III study
  • Sep 04, 2019: Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy product
  • Aug 02, 2019: Helixmith unveils results for neuromuscular disease treatment
  • Jul 16, 2019: Athira Pharma presents preliminary results from phase 1 trial of NDX-1017 at Alzheimer's Association International Conference 2019 (AAIC)
  • May 27, 2019: Yooyoung Pharmaceutical: YYB101 -- refractory solid tumor treatment
  • May 01, 2019: Athira Pharma announces appointment of Dr. Hans J. Moebius as chief medical officer
  • Mar 26, 2019: AnGes obtains conditional approval in Japan for HGF gene therapy to treat critical limb ischemia
  • Feb 21, 2019: Japanese approval of HGF gene therapy drug, as the first gene therapy product to be launched in Japan
  • Feb 12, 2019: AnGes and Kamada entered into agreement for the commercialization of HGF gene therapy product in Israel
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer